Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. is establishing a joint venture with Zhongyu Pet Food (Luohe) Co., Ltd. to enhance its strategic layout in the animal health non-drug sector, leveraging both companies' resources and capabilities in the pet food market [1][2]. Group 1: Joint Venture Details - The joint venture will be named Zhejiang Haizheng Zhongyu Animal Nutrition Technology Co., Ltd. and will focus on the production, research, and sales of pet prescription food [2][3]. - The registered capital of the joint venture is set at 50 million RMB, with Haizheng Animal Health contributing 30 million RMB (60%) and Zhongyu Pet Food contributing 20 million RMB (40%) [3][4]. - Haizheng Animal Health will contribute its 100% stake in Haizheng Nutrition Technology, valued at approximately 9.93 million RMB, along with cash [3][4]. Group 2: Financial and Operational Background - Zhongyu Pet Food reported total assets of 562.82 million RMB and a net profit of 72.64 million RMB for the year ending December 31, 2024, with a significant increase in assets to 896.95 million RMB and net profit of 84.94 million RMB for the first nine months of 2025 [2][3]. - The joint venture aims to invest a total of 236.1 million RMB in future projects, with 204.26 million RMB requiring approval, and plans to finance through shareholder contributions and commercial loans [5][6]. Group 3: Governance and Rights - The joint venture's governance structure includes a board of directors with five members, where Haizheng Animal Health can nominate three directors and Zhongyu Pet Food can nominate two [9]. - Shareholders have rights regarding equity transfer restrictions, preemptive rights for future capital increases, and access to company information [10][12][13]. Group 4: Compliance and Restrictions - The joint venture will adhere to competitive restrictions, preventing shareholders from engaging in competing businesses during their shareholding period and for one year after [16][17]. - Any breach of obligations under the agreement will result in liability for damages, including legal fees [18][19].

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has announced the establishment of a joint venture with Zhongyu Pet Food (Luohe) Co., Ltd. to enhance its strategic layout in the animal health non-drug sector, particularly in pet food production and sales [1][23]. Group 1: Joint Venture Details - The joint venture will be named Zhejiang Haizheng Zhongyu Animal Nutrition Technology Co., Ltd. and will focus on the production, research, and sales of pet prescription food [5][6]. - Haizheng Dongbao will contribute 3,000 million RMB (60% of the registered capital) and Zhongyu Pet Food will contribute 2,000 million RMB (40% of the registered capital) [5][6]. - The total investment planned for the joint venture's future projects is 236.1 million RMB, with 204.3 million RMB requiring approval [8]. Group 2: Financial and Operational Background - Zhongyu Pet Food reported total assets of 562.82 million RMB and a net profit of 72.64 million RMB for the year 2024, with a revenue of 627.77 million RMB [4]. - As of September 30, 2025, Zhongyu Pet Food's total assets increased to 896.95 million RMB, with a net profit of 84.94 million RMB for the first nine months of 2025 [4]. Group 3: Governance and Rights - The joint venture's governance structure includes a board of directors with five members, where Haizheng Dongbao can nominate three directors and Zhongyu Pet Food can nominate two [11]. - Shareholders have rights to information, including access to accounting records and other relevant data [15]. Group 4: Project Development and Financing - The project will be developed in two phases over four years, with a total investment of 497.17 million RMB, including construction costs and working capital [23][24]. - The company plans to apply for a bank loan of 334.12 million RMB to fund the construction phase [23].